Skip to main content
Premium Trial:

Request an Annual Quote

NIH Grants New England Biolabs $640K for Epigenetic Tools Development

NEW YORK (GenomeWeb News) – New England Biolabs announced Thursday that it has received a $640,000 Phase II Small Business Innovation grant from the National Institutes of Health to expand its research into development of enzymatic tools for epigenetic analysis.

The Ipswich, Mass.-based company said it has focused on using restriction enzymes in epigenetic studies for years, and research into methylation-dependent and methylation-sensitive restriction enzymes has resulted in new tools for identifying such DNA modifications. The grant announced today will enable additional research into this area, resulting in "a deeper understanding of epigenetic marks in the mammalian genome."

In 2010 New England Biolabs received an SBIR grant for $1.2 million for research into and the development of enzymatic reagents for epigenetics. It said today that it has received more than $1.1 million in SBIR funds since 2009.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.